March 19, 2020 In December 2019, a new virus called SARS-COV-2 was identified in Wuhan, China. This virus was found to cause a severe respiratory illness in patients which was later named after the type of virus that caused it and the year it was identified (coronavirus disease 2019 or COVID-19)1 Currently there is no […] READ MORE
18 de marzo de 2020 Estimados amigos: Su bienestar es la máxima prioridad para todos nosotros en la Alianza para la investigación de Lupus (Lupus Research Alliance, LRA). Estamos consultando a los mejores clínicos y científicos especializados en lupus para supervisar la situación planteada por la propagación del coronavirus SARS (SARS-CoV-2), comúnmente denominado COVID-19, en […] READ MORE
March 18, 2020 Dear Friends, Your well-being is the utmost priority for all of us at the Lupus Research Alliance (LRA). We are consulting with top lupus clinicians and scientists in monitoring the situation posed by the spread of the SARS coronavirus (SARS-CoV-2) often referred to as COVID-19, across the world and committed to doing […] READ MORE
13 de marzo de 2020 La prioridad de Lupus Research Alliance es la salud de las personas que viven con lupus. Nos estamos asesorando con las autoridades sanitarias y estamos monitoreando la situación causada por la propagación de la enfermedad por coronavirus denominada COVID-19. La siguiente es una lista de preguntas frecuentes para ayudar a […] READ MORE
March 16, 2020 The Lupus Research Alliance is pleased to share an announcement from Aurinia Pharmaceuticals that moves its potential treatment for lupus nephritis, voclosporin, one step closer to approval by the U.S. Food and Drug Administration (FDA). The Company announced in a press release March 16 that it has started a Rolling Submission of […] READ MORE
Updated April 3, 2020 The first priority of the Lupus Research Alliance is the health of our lupus community. We have been consulting with health care authorities and monitoring the situation created by the spread of COVID-19. Please note that every lupus patient is different. If you have specific questions about your condition and/or any […] READ MORE
March, 2020 Congress will be working on the Fiscal Year 2021 budget for weeks to come, so you can still make your voice heard for lupus research. If you haven’t already, please go online TODAY and use the automated tools of our Legislative Action Center to tell legislators what lupus research means to their constituents […] READ MORE
March 9, 2020 A newly published study showed that antimalarial medications, a common form of treatment for lupus, may help prevent type 2 diabetes mellitus (T2DM), which can be a complication of the disease and a side effect of medications like glucocorticosteroids. Researchers reviewed health databases in British Columbia Canada to study the incidence of […] READ MORE
March 4, 2020 A new study showed that living in a disadvantaged neighborhood predicts poor retention (follow-up) care for people with lupus. Retention was defined specifically has having two out-patient doctor visits or lab tests such as measuring complement levels. Researchers looked at the records of 397 patients with lupus in terms of age, sex, […] READ MORE
Updated March 11, 2020 On behalf of our lupus community, the Lupus Research Alliance is following closely reports from the U.S. Centers for Disease Control and Prevention (CDC), the country’s health protection agency, about the Coronavirus Disease 2019 called COVID-19. People with lupus are predisposed (at greater risk) to infections because of both their disease […] READ MORE
Poner al día 11 Marzo de 2020 En nombre de nuestra comunidad de lupus, la Alianza para la investigación de Lupus (Lupus Research Alliance) está siguiendo de cerca los informes de los Centros para el Control y la Prevención de Enfermedades de los Estados Unidos (CDC), la agencia de protección de la salud del país, […] READ MORE
February 27, 2020 A new study supported by the Lupus Research Alliance discovered that molecules called type II interferons can trigger the immune system to over-produce the B cells that cause lupus inflammation. Type I interferons have already been shown to be very important in lupus which has led to exciting new drugs like anifrolumab […] READ MORE
